Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty


Contact us for more batch information
Select Batch
Resource Download


Catalog No. TQ0169Cas No. 33627-41-7
Inulicin (1-O-Acetylbritannilactone), an active compound isolated from Inula Britannica L, inhibits VEGF-mediated activation of Src and FAK.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Pack SizePriceAvailabilityQuantity
1 mg$51In Stock
5 mg$163In Stock
10 mg$250In Stock
25 mg$418In Stock
50 mg$623In Stock
100 mg$887In Stock
1 mL x 10 mM (in DMSO)$178In Stock
Bulk & Custom
Add to Cart
View More

Related Compound Libraries of "Inulicin"

Product Introduction

Inulicin (1-O-Acetylbritannilactone), an active compound isolated from Inula Britannica L, inhibits VEGF-mediated activation of Src and FAK.
In vitro
Inulicin (1-O-Acetylbritannilactone) inhibits angiogenesis and lung cancer cell growth through regulating VEGF-Src-FAK signaling. Inulicin dose-dependently inhibits vascular endothelial growth factor (VEGF)-induced proliferation, migration, and capillary structure formation of cultured human umbilical vascular endothelial cells (HUVECs). Significant high levels of Src and FAK phosphorylations are noticed in A549 cells, which are both inhibited by the treatment of Inulicin (5 μM and 10 μM). Src and FAK are both important for cancer cell proliferation. Thus, A549 cell growth, tested by MTT assay and clonogenicity assay, is remarkably inhibited by corresponding Inulicin treatment. The anti-A549 cell growth activity of Inulicin is again dose-dependent [1]. Inulicin (5, 10, 20 μM) has several concentration-dependent effects, including inhibition of lipopolysaccharide (LPS)-induced PGE2 production and COX-2 expression, and blockade of NF-κB activation and translocation. In addition, Inulicin directly inhibits the binding of active NF-κB to specific DNA cis-element [2].
In vivo
Administration of a single dose of Inulicin (12 mg/kg/day) remarkably suppresses the growth of A549 xenografts in nude mice. In vivo, microvessels formation and Src activation are also significantly inhibited in Inulicin-treated xenograft tumors. A single dose of Inulicin (12 mg/kg/day, i.p.) dramatically inhibits the growth of A549 xenografts in nude mice. Further, the weights of Inulicin-treated tumors are remarkably lighter than that of vehicle-treated tumors [1].
Cell Research
HUVECs or A549 cells are plated in 60 mm plates (300 cells/plate). After overnight incubation, cells are treated with applied agents (Inulicin; 5 μM and 10 μM) for 24 h. Cells are then washed, and fresh media are added. After 10 days of incubation, surviving colonies are fixed, stained, and manually counted [1].
Animal Research
Male nude mice (4-6weeks old, BALB/c) are used. A549 cells (five million cells in 0.1 mL of culture medium) are subcutaneously injected at the right thigh of nude mice, and treatment is started when the tumors reach an average volume of about 100 mm3. Animals are randomized into two groups with 10 mice per group: (a) Vehicle; (b) 12 mg/kg of Inulicin. Inulicin is injected intraperitoneally (i.p.) daily. The mice are examined daily for toxicity/mortality relevant to treatment, and the tumor is measured with a caliper every two days. The tumor volume (in mm3) is calculated, and the tumor growth curve is presented. At the end of experiments, xenograft tumors are isolated through surgery and weighted [1].
Chemical Properties
Molecular Weight308.37
Cas No.33627-41-7
Storage & Solubility Information
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Solubility Information
Ethanol: 45 mg/mL (145.93 mM)
Solution Preparation Table
1 mM3.2429 mL16.2143 mL32.4286 mL162.1429 mL
5 mM0.6486 mL3.2429 mL6.4857 mL32.4286 mL
10 mM0.3243 mL1.6214 mL3.2429 mL16.2143 mL
20 mM0.1621 mL0.8107 mL1.6214 mL8.1071 mL
50 mM0.0649 mL0.3243 mL0.6486 mL3.2429 mL
100 mM0.0324 mL0.1621 mL0.3243 mL1.6214 mL


  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
1 Enter information below:
2 Enter the in vivo formulation:
%Tween 80

Dose Conversion

You can also refer to dose conversion for different animals. More

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc